Alpha Tau Medical Ltd
DRTSHealthcare|Biotechnology|IL
$13.72
+0.42 (+3.16%)
Tangible Book / Share
$0.48
Cash / Share
$1.11
Financials
Financial Snapshot
Market Cap
$1.27B
Enterprise Value
$1.26B
Revenue (TTM)
$0.00
Net Income (TTM)
-$92.6M
Cash & Investments
$100.6M
Net Cash
$85.5M
Free Cash Flow (TTM)
-$32.8M
Operating CF (TTM)
-$26.7M
Debt/Equity
0.34
Cash Runway & Burn Rate
Cash on Hand
$100.6M
Quarterly Burn
$6.7M
Monthly Burn
$2.2M
Est. Runway
~15.1 quarters
| Metric | Trend | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|
| Cash & Investments | $28.1M | $46.0M | $31.3M | $104.5M | $81.8M | $59.6M | $76.9M | $100.6M | |
| Operating Cash Flow | -$6.9M | -$7.3M | -$11.8M | -$23.9M | -$18.0M | -$19.8M | -$26.7M | -$26.7M | |
| Free Cash Flow | -$8.2M | -$11.0M | -$14.7M | -$24.8M | -$24.4M | -$22.0M | -$32.8M | -$32.8M | |
| Capital Expenditure | -$1.3M | -$3.8M | -$2.9M | -$904.0K | -$6.4M | -$2.2M | -$6.1M | -$6.1M | |
| Financing Cash Flow | $5.3M | $29.3M | $111.0K | $96.9M | $5.3M | $25.0K | $45.8M | $45.8M |
R&D Spending
R&D (TTM)
$38.8M
R&D Intensity
—
R&D Growth vs Prior
+25.7%
| Metric | Trend | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| R&D Expense | $6.6M | $7.5M | $11.4M | $20.9M | $26.4M | $27.0M | $30.8M | $38.8M | |
| SG&A | $1.4M | $1.7M | $2.3M | $11.2M | $9.3M | $9.0M | $10.2M | $11.7M |
Income Statement
| Metric | Trend | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Cost of Revenue | $0.00 | $86.0K | $0.00 | $0.00 | $0.00 | $0.00 | $1.2M | $0.00 | |
| Gross Profit | $0.00 | -$86.0K | $0.00 | $0.00 | $0.00 | $0.00 | -$1.2M | $0.00 | |
| R&D | $6.6M | $7.5M | $11.4M | $20.9M | $26.4M | $27.0M | $30.8M | $38.8M | |
| SG&A | $1.4M | $1.7M | $2.3M | $11.2M | $9.3M | $9.0M | $10.2M | $11.7M | |
| Operating Income | -$8.0M | -$9.2M | -$13.8M | -$32.1M | -$35.7M | -$36.0M | -$42.3M | -$50.4M | |
| Interest Expense | $0.00 | $217.0K | $0.00 | $0.00 | $75.0K | $303.0K | $419.0K | $41.4M | |
| Pretax Income | -$8.3M | -$8.7M | -$27.3M | -$33.7M | -$29.1M | -$31.7M | -$42.5M | -$92.4M | |
| Net Income | -$8.5M | -$8.9M | -$27.3M | -$33.8M | -$29.2M | -$31.8M | -$42.6M | -$92.6M | |
| EPS (Diluted) | -0.13 | -0.13 | -0.40 | -0.53 | -0.42 | -0.45 | -0.53 | -1.04 | |
| EBITDA | -$7.9M | -$9.2M | -$26.5M | -$32.8M | -$28.0M | -$30.3M | -$41.1M | -$49.1M | |
| Shares Out. (M) | 67.62 | 67.62 | 67.62 | 63.53 | 69.38 | 69.93 | 80.58 | 90.95 |
Balance Sheet
| Metric | Trend | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $1.8M | $15.6M | $23.2M | $5.8M | $12.7M | $13.7M | $16.0M | $23.0M | |
| Short-Term Investments | $26.3M | $30.4M | $8.1M | $98.7M | $69.1M | $45.9M | $60.9M | $77.6M | |
| Total Current Assets | $29.8M | $47.5M | $32.6M | $106.5M | $85.8M | $64.2M | $78.3M | $106.8M | |
| Total Assets | $31.6M | $53.0M | $42.2M | $120.1M | $107.4M | $86.2M | $106.6M | $134.3M | |
| Total Current Liabilities | $1.3M | $2.1M | $4.4M | $4.3M | $7.1M | $8.7M | $10.5M | $9.6M | |
| Long-Term Debt | $0.00 | $54.0M | $54.0M | $0.00 | $5.6M | $5.6M | $6.4M | $6.8M | |
| Total Liabilities | $31.8M | $61.4M | $77.0M | $14.5M | $22.9M | $23.5M | $29.5M | $90.2M | |
| Stockholders' Equity | -$193.0K | -$8.4M | -$34.8M | $105.7M | $84.5M | $62.7M | $77.1M | $44.1M | |
| Retained Earnings | -$16.7M | -$25.6M | -$52.8M | -$86.6M | -$115.8M | -$147.5M | -$190.1M | -$258.9M |
Cash Flow Statement
| Metric | Trend | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$6.9M | -$7.3M | -$11.8M | -$23.9M | -$18.0M | -$19.8M | -$26.7M | -$26.7M | |
| Capital Expenditure | -$1.3M | -$3.8M | -$2.9M | -$904.0K | -$6.4M | -$2.2M | -$6.1M | -$6.1M | |
| Free Cash Flow | -$8.2M | -$11.0M | -$14.7M | -$24.8M | -$24.4M | -$22.0M | -$32.8M | -$32.8M | |
| Investing Cash Flow | -$10.2M | -$7.8M | $19.3M | -$89.9M | $18.7M | $20.8M | -$20.6M | -$20.6M | |
| Financing Cash Flow | $5.3M | $29.3M | $111.0K | $96.9M | $5.3M | $25.0K | $45.8M | $45.8M | |
| Issuance of Stock | $5.3M | $29.3M | $111.0K | $3.4M | $49.0K | $25.0K | $45.8M | $45.8M | |
| Repurchase of Stock | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Net Debt Issuance | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Stock Based Comp. | $546.0K | $596.0K | $812.0K | $6.7M | $7.9M | $9.9M | $0.00 | $6.7M | |
| Net Change in Cash | -$11.8M | $16.2M | $7.7M | -$17.2M | $9.1M | $1.2M | -$1.0M | -$6.8M |
Dilution Tracker
Shares Outstanding
92M
5-Year Share Growth
+19.2%
Stock Issuance (TTM)
$45.8M
| Metric | Trend | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|
| Shares Out. (M) | 67.62 | 67.62 | 67.62 | 63.53 | 69.38 | 69.93 | 80.58 | 90.95 | |
| Change vs Prior % | — | 0.0% | 0.0% | -6.0% | 9.2% | 0.8% | 15.2% | 12.9% | |
| Stock Issuance | $5.3M | $29.3M | $111.0K | $3.4M | $49.0K | $25.0K | $45.8M | $45.8M | |
| Stock Repurchase | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Stock Based Comp. | $546.0K | $596.0K | $812.0K | $6.7M | $7.9M | $9.9M | $0.00 | $6.7M |
Margins & Profitability
| Metric | Trend | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|
| ROE % | 4385.5% | 105.4% | 78.4% | -32.0% | -34.5% | -50.7% | -55.3% | -138.1% | |
| ROA % | -26.8% | -16.8% | -64.6% | -28.1% | -27.2% | -36.8% | -40.0% | -69.0% | |
| ROIC % | -26.5% | -18.2% | -36.5% | -27.6% | -35.2% | -45.9% | -43.5% | -40.0% |
Growth (Year over Year)
Fiscal years. Rising share count growth means dilution.
| Metric | Trend | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Gross Profit | 0.0% | 0.0% | 100.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Operating Income | 0.0% | -15.4% | -49.2% | -133.0% | -11.0% | -1.0% | -17.3% | |
| Net Income | 0.0% | -4.9% | -207.0% | -23.8% | 13.6% | -8.9% | -34.3% | |
| EPS (Diluted) | 0.0% | 0.0% | -207.7% | -32.5% | 20.8% | -7.1% | -17.8% | |
| Operating Cash Flow | 0.0% | -4.9% | -62.9% | -102.2% | 24.8% | -10.2% | -34.9% | |
| Free Cash Flow | 0.0% | -34.3% | -33.8% | -68.1% | 1.7% | 9.6% | -48.7% | |
| R&D Expense | 0.0% | 12.4% | 53.5% | 82.5% | 26.5% | 2.3% | 14.1% | |
| SG&A Expense | 0.0% | 23.7% | 37.8% | 380.0% | -17.7% | -2.5% | 13.3% | |
| Total Assets | 0.0% | 67.9% | -20.3% | 184.6% | -10.6% | -19.7% | 23.6% | |
| Book Value / Share | 0.0% | -4267.4% | -312.6% | 423.4% | -26.8% | -26.4% | 6.8% | |
| Debt | 0.0% | 0.0% | 0.0% | -90.4% | 155.7% | -5.6% | 9.5% | |
| Diluted Shares | 0.0% | 0.0% | 0.0% | -6.0% | 9.2% | 0.8% | 15.2% |
Valuation
P/E (TTM)At Loss
P/S0.00
P/B28.33
10Y Low / Med / High1.91 / 3.46 / 5.17
EV/EBITDAAt Loss
EV/Revenue0.00
P/FCFAt Loss
Intrinsic Value Models (per share)
Tangible Book / Share
$0.48
Net Current Assets / Share
$0.18
Graham Net-Net
$0.11
Cash / Share
$1.11
| Metric | Trend | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio | -77.69 | -77.69 | -24.55 | -6.00 | -7.17 | -6.89 | -9.34 | -13.19 | |
| P/S Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| P/B Ratio | -3538.74 | -81.03 | -19.09 | 1.91 | 2.47 | 3.46 | 5.17 | 28.33 | |
| EV/EBITDA | -85.74 | -78.77 | -26.23 | -6.15 | -7.48 | -7.11 | -9.66 | -25.70 | |
| EV/Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Analyst Estimates & Quality
Altman Z-Score
5.37
Safe
Piotroski F-Score
2
Weak
Forward Estimates (consensus)
| Metric | FY2026 | FY2027 | FY2028 |
|---|---|---|---|
| Revenue | $708.3K | $12.6M | $73.8M |
| Net Income | -$77.0M | -$43.1M | -$34.7M |
| EPS | $-0.96 | $-0.53 | $-0.37 |
| # Analysts (EPS) | 4 | 4 | 2 |